Related Experiment Video
Updated: Jun 27, 2026
09:04
DNBS/TNBS Colitis Models: Providing Insights Into Inflammatory Bowel Disease and Effects of Dietary Fat
Published on: February 27, 2014
Plasma lipids and inflammation in active inflammatory bowel diseases
G Romanato1, M Scarpa, I Angriman
1CNR-Institute of Neurosciences-Aging Section, Padova, Italy. giovanna.romanato@unipd.it
Alimentary Pharmacology & Therapeutics
|November 28, 2008
Summary
In patients with active ulcerative colitis (UC) and Crohn's disease (CD), cholesterol levels were lower and linked to inflammation. Phospholipid fatty acid (FA) composition also correlated with systemic inflammation.
Area of Science:
- Gastroenterology
- Clinical Nutrition
- Biochemistry
Background:
- Ulcerative colitis (UC) and Crohn's disease (CD) are inflammatory bowel diseases associated with metabolic changes.
- Understanding these metabolic alterations is crucial for managing patient health.
Purpose of the Study:
- To investigate the links between inflammatory markers, plasma lipids, and phospholipid fatty acid (FA) profiles in active UC and CD patients.
- To explore correlations between these parameters and disease activity.
Main Methods:
- Assessed diet, disease activity (Harvey-Bradshaw Activity Index - HBAI), inflammatory markers (e.g., C-reactive protein - CRP), lipoproteins, and FA composition in 60 CD and 34 UC patients.
- Utilized multiple regression analysis to identify independent associations.
Main Results:
- Total and LDL cholesterol were lower in active UC and CD patients compared to healthy individuals.
- Cholesterol levels and specific FAs (arachidonic acid, docosapentaenoic acid) showed correlations with inflammatory markers (CRP, HBAI) and clinical parameters (bowel movements, BMI).
- Total cholesterol was independently associated with bowel movement frequency and systemic inflammation.
Conclusions:
- Active UC and CD are associated with reduced total and LDL cholesterol, correlating with systemic inflammation.
- Phospholipid FA composition is linked to the systemic inflammatory status in these patients.
- Dietary intake and intestinal disease activity were not directly correlated with phospholipid FA composition.
Related Concept Videos
01:20Inflammatory Bowel Disease II: Ulcerative Colitis
Ulcerative colitis is a chronic inflammatory disorder of the colon characterized by continuous mucosal inflammation that typically begins in the rectum and extends proximally in a uniform pattern. Its pathogenesis involves a complex interplay of genetic predisposition, immune dysregulation, and environmental influences. These factors converge to impair the colon’s epithelial defenses and promote an exaggerated inflammatory response against luminal contents.Breakdown of the Mucosal BarrierA...
01:20Inflammatory Bowel Disease IV: Clinical Manifestations
Inflammatory bowel disease (IBD) encompasses two major chronic disorders—ulcerative colitis and Crohn’s disease—each characterized by relapsing episodes of gastrointestinal inflammation. Although they share certain clinical features, their patterns of involvement and manifestations differ in ways that aid diagnosis and guide management.Ulcerative ColitisUlcerative colitis is limited to the colon and rectum and involves continuous inflammation of the mucosal layer. The disease course is marked...
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
01:29Inflammatory Bowel Disease IV: Pharmacological Management
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
01:25Inflammatory Bowel Disease III: Crohn's Disease
Crohn’s disease is a chronic, relapsing form of inflammatory bowel disease characterized by segmental, transmural inflammation that can affect any part of the gastrointestinal tract. Its pathogenesis arises from a combination of genetic susceptibility, environmental exposures, epithelial barrier dysfunction, and immune dysregulation. Together, these factors lead to an exaggerated immune response against components of the gut microbiome.Genetic and Environmental InfluencesMultiple genetic...
01:30Inflammatory Bowel Disease II: Crohn's Disease
Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by transmural...
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by transmural...